COMMUNIQUÉS West-GlobeNewswire

Publishing of Orion Corporation's Financial Statement Release for 2017 on 7 February 2018
24/01/2018
ORION CORPORATION PRESS RELEASE 24 JANUARY 2018 at 11.45 A.M. EET Publishing of Orion Corporation's Financial Statement Release for 2017 on 7 February 2018 Orion will publish its Financial Statement Release for 2017 on [...]
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
24/01/2018
Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto , more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1 billion in 2017, USD 615 [...]
Novartis a enregistré, en 2017, une belle performance opérationnelle et des innovations majeures, entrant ainsi dans une nouvelle phase de croissance
24/01/2018
Hausse de 2% (tcc, +1% USD) des ventes sur l'exercice complet, car l'excellente performance de nos moteurs de croissance, notamment Cosentyx et Entresto , a plus que compensé l'érosion due aux génériques de Gleevec/ [...]
ABLYNX APPOINTS DR ROBERT FRIESEN AS CHIEF SCIENTIFIC OFFICER
24/01/2018
GHENT, Belgium, 24 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced the appointment of Robert Friesen, PhD, as Chief Scientific Officer (CSO), effective 1 March 2018. Dr Friesen will lead the [...]
Insmed Announces Pricing of Public Offering of Convertible Senior Notes
24/01/2018
BRIDGEWATER, N.J., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ) announced today that it priced its registered underwritten public offering of $400 million aggregate principal amount of its 1.75 [...]
Ultragenyx Announces Pricing of Public Offering of Common Stock
24/01/2018
NOVATO, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today [...]
Adamas Announces Pricing of Public Offering of Common Stock
24/01/2018
EMERYVILLE, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS ) today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to [...]
Radient Technologies Inc. Announces Shares for Services Issuance
24/01/2018
EDMONTON, Alberta, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Corporation”) (TSX Venture:RTI) announces that the Corporation has issued an aggregate of 28,024 common shares to third [...]
HealthEquity to Announce Year-End HSAs and Custodial Assets
24/01/2018
DRAPER, Utah, Jan. 23, 2018 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY ) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA”) non-bank custodian, today announced that it plans [...]
National Research Corporation Chief Executive Officer Continues Estate Plan
24/01/2018
Lincoln, Nebraska, Jan. 23, 2018 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ: NRCIA and NRCIB) today announced that over the next few weeks, CEO Michael D. Hays will be gifting and/or transferring his [...]
Sanofi: Availability of the Pre-quarterly Results Communication
23/01/2018
Availability of the Pre-quarterly Results Communication Paris, France - January 23, 2018 - Sanofi announced today that its Pre-Quarterly Results Communication document is available on the "Investors" page of the company [...]
Sanofi : Mise en ligne du document «Pre-quarterly Results Communication »
23/01/2018
Mise en ligne du document «Pre-quarterly Results Communication » Paris, France - Le 23 janvier 2018 - Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « [...]
Cocrystal Pharma Provides Update on Reverse Stock Split
23/01/2018
- Reverse stock split to be effective on Wednesday, January 24, 2018 on split-adjusted basis under trading symbol “COCPD” - ATLANTA, GA and BOTHELL, WA, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB: [...]
MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis
23/01/2018
Rockville, MD, Jan. 23, 2018 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (NASDAQ: MGNX ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics [...]
Strongbridge Biopharma plc Announces Proposed Public Offering of 5 Million Ordinary Shares
23/01/2018
DUBLIN, Ireland and TREVOSE, Pa., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP ) (the “Company”) today announced that it intends to offer and sell 5 million of its ordinary shares in an [...]
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
23/01/2018
RA’ANANA, Israel and NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN ), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with [...]
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
23/01/2018
CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO ) today announced the closing of its previously announced underwritten public offering of common stock, including the [...]
HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
23/01/2018
TUCSON, Ariz., Jan. 23, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM ) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the [...]
Five Prime Announces Proposed Public Offering of Common Stock
23/01/2018
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX ), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology [...]

Pages